Q3 EARNINGS: bioMérieux gets warning letter; Intuitive recovery continues; Thermo lowers guidance
This article was originally published in Clinica
Executive Summary
bioMérieux’s third quarter was “broadly in line” with expectations, according to Jefferies analyst Peter Welford. Q3 sales of €412m ($523m) grew 6% year-on-year, with 2.3% organic growth similar to his prediction of 2.6%, but “shy of +3.1% consensus.”